Hsbc Holdings PLC Arcus Biosciences, Inc. Transaction History

Hsbc Holdings PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $272,273 - $493,547	13,821 New	13,821 $285,000
Q1 2021 May 14, 2021	SELL	$26.16 - $41.39 $388,371 - $614,475	-14,846 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$17.0 - $32.36 $64,991 - $123,712	3,823 Added 34.68%	14,846 $385,000
Q3 2020 Nov 12, 2020	BUY	$17.14 - $25.47 $188,934 - $280,755	11,023 New	11,023 $191,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.